Variables | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Age, years, ≥70 vs. <70 | 0.857 (0.539–1.362) | 0.513 |  |  |
Sex, men vs. women | 1.354 (0.814–2.255) | 0.243 |  |  |
BMI, kg/m2, ≥25.0 vs. <25.0 | 0.731 (0.444–1.204) | 0.218 |  |  |
Baseline L3 SMI, low SMI vs. high SMI | 1.405 (0.861–2.293) | 0.174 |  |  |
ΔL3 SMI, SML vs. non-SML | 1.750 (1.093–2.800) | 0.020 | 1.675 (1.031–2.721) | 0.037 |
ALT, U/L, ≥30 vs. <30 | 1.046 (0.650–1.682) | 0.854 |  |  |
Total bilirubin, mg/dL, ≥1.5 vs. <1.5 | 1.690 (1.002–2.851) | 0.049 | 1.747 (0.897–3.403) | 0.101 |
Albumin, g/dL, ≥3.5 vs. <3.5 | 0.595 (0.361–0.982) | 0.042 | 0.697 (0.386–1.259) | 0.231 |
Platelet count, ×104/μL, ≥10.0 vs. <10.0 | 0.971 (0.607–1.552) | 0.902 |  |  |
Child-Pugh classification, A vs. B | 0.638 (0.395–1.030) | 0.066 |  |  |
AFP, ng/mL, ≥20 vs. <20 | 2.618 (1.615–4.241) | <  0.001 | 2.550 (1.440–4.515) | 0.001 |
TNM stage, I + II vs. III + IV | 0.785 (0.474–1.300) | 0.347 |  |  |
Maximum tumor diameter, mm, ≥30 vs. <30 | 1.936 (1.195–3.135) | 0.007 | 1.925 (1.166–3.179) | 0.010 |
Number of tumors, solitary vs. multiple | 0.961 (0.572–1.614) | 0.880 |  |  |
Treatment sessions between CT exams, sessions, 1 vs. ≥ 2 | 0.696 (0.433–1.119) | 0.135 |  |  |
mRECIST assessment, non-PD vs. PD | 0.444 (0.277–0.712) | 0.001 | 0.653 (0.392–1.088) | 0.102 |
BCAA supplementation, presence vs. absence | 1.614 (0.898–2.900) | 0.110 |  |  |